Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Stallergenes Greer's Enterprise Value is $811.38 Mil.
Stallergenes Greer's EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $20.63 Mil. Therefore, Stallergenes Greer's EV-to-EBIT ratio for today is 39.32.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Stallergenes Greer's Enterprise Value is $811.38 Mil.
Stallergenes Greer's EBITDA for the trailing twelve months (TTM) ended in Dec. 2018 was $45.49 Mil. Therefore, Stallergenes Greer's EV-to-EBITDA ratio for today is 17.84.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Stallergenes Greer's Enterprise Value is $811.38 Mil.
Stallergenes Greer's Revenue for the trailing twelve months (TTM) ended in Dec. 2018 was $319.54 Mil. Therefore, Stallergenes Greer's EV-to-Revenue ratio for today is 2.54.
Stallergenes Greer Enterprise Value Historical Data
The historical data trend for Stallergenes Greer's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Stallergenes Greer's Enterprise Value
For the Biotechnology subindustry, Stallergenes Greer's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stallergenes Greer's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stallergenes Greer's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Stallergenes Greer's Enterprise Value falls into.
Stallergenes Greer Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Stallergenes Greer's Enterprise Value for the fiscal year that ended in Dec. 2018 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stallergenes Greer (GREY:STLLF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Stallergenes Greer's current Enterprise Value is $811.38 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Stallergenes Greer's EBIT for the trailing twelve months (TTM) ended in Dec. 2018 was $20.63 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Stallergenes Greer's current Enterprise Value is $811.38 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Stallergenes Greer's EBITDA for the trailing twelve months (TTM) ended in Dec. 2018 was $45.49 Mil.
Stallergenes Greer's current Enterprise Value is $811.38 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Stallergenes Greer's Revenue for the trailing twelve months (TTM) ended in Dec. 2018 was $319.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stallergenes Greer Enterprise Value Related Terms
Thank you for viewing the detailed overview of Stallergenes Greer's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Stallergenes Greer (Stallergenes Greer) Business Description
Stallergenes Greer PLC is a pharmaceutical company. The company treats severe allergic rhinitis with allergen immunotherapy. Its portfolio comprises of Sublingual products, Subcutaneous products, Veterinary products and Other. The sublingual products are offered under the brand name Staloral and Oralair. The Subcutaneous products include Phostal, Alustal, Alyostal, Albey. The company also offers enzyme-linked immunosorbent assay components and prescription services. It provides skin testing devices enabling the identification of the allergen or allergens responsible for the allergy, sterile diluents and sterile empty vials, syringes, and other compendial products. The company operates in internationally and geographically generates maximum revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STLLF has been successfully added to your 